{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:28:58Z","timestamp":1784806138527,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Motamed Cancer Institute, ACECR, Tehran, Iran"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-01080-1","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T09:28:39Z","timestamp":1767691719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic combination of pirfenidone and paclitaxel suppresses migration and stemness in triple-negative breast cancer: implications of EMT and pluripotency pathways"],"prefix":"10.1186","volume":"27","author":[{"given":"Nima","family":"Rastegar-Pouyani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnaz","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Khazen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohadeseh","family":"Haji Abdolvahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"2","key":"1080_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.25122\/jml-2021-0108","volume":"15","author":"A Baranova","year":"2022","unstructured":"Baranova A, Krasnoselskyi M, Starikov V, Kartashov S, Zhulkevych I, Vlasenko V, et al. Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. J Med Life. 2022;15(2):153.","journal-title":"J Med Life"},{"issue":"7","key":"1080_CR2","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023;15(7):1796.","journal-title":"Pharmaceutics"},{"key":"1080_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctrv.2016.09.004","volume":"50","author":"F Schettini","year":"2016","unstructured":"Schettini F, Giuliano M, De Placido S, Arpino G. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Cancer Treat Rev. 2016;50:129\u201341.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1080_CR4","doi-asserted-by":"publisher","first-page":"3687700","DOI":"10.1155\/2021\/3687700","volume":"2021","author":"J Sharifi-Rad","year":"2021","unstructured":"Sharifi-Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Das G, et al. Paclitaxel: application in modern oncology and nanomedicine-based cancer therapy. Oxidative Med Cell Longev. 2021;2021(1):3687700.","journal-title":"Oxidative Med Cell Longev"},{"key":"1080_CR5","doi-asserted-by":"publisher","first-page":"111824","DOI":"10.1016\/j.biopha.2021.111824","volume":"141","author":"M Ashrafizadeh","year":"2021","unstructured":"Ashrafizadeh M, Mirzaei S, Hashemi F, Zarrabi A, Zabolian A, Saleki H, et al. New insight towards development of Paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomed Pharmacother. 2021;141:111824.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1080_CR6","doi-asserted-by":"publisher","first-page":"e3002487","DOI":"10.1371\/journal.pbio.3002487","volume":"22","author":"T Celi\u00e0-Terrassa","year":"2024","unstructured":"Celi\u00e0-Terrassa T, Kang Y. How important is EMT for cancer metastasis? PLoS Biol. 2024;22(2):e3002487.","journal-title":"PLoS Biol"},{"issue":"5","key":"1080_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","volume":"31","author":"J-J Loh","year":"2024","unstructured":"Loh J-J, Ma S. Hallmarks of cancer stemness. Cell Stem Cell. 2024;31(5):617\u201339.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1080_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.canlet.2013.06.020","volume":"341","author":"WM ElShamy","year":"2013","unstructured":"ElShamy WM, Duh\u00e9 RJ. Overview: cellular plasticity, cancer stem cells and metastasis. Cancer Lett. 2013;341(1):2\u20138.","journal-title":"Cancer Lett"},{"key":"1080_CR9","doi-asserted-by":"crossref","unstructured":"Skvortsova I. Cancer stem cells: what do we know about them? MDPI; 2021. p. 1528.","DOI":"10.3390\/cells10061528"},{"issue":"12","key":"1080_CR10","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.17219\/acem\/140590","volume":"30","author":"FM I\u00e7duygu","year":"2021","unstructured":"I\u00e7duygu FM, Samli H, \u00d6zg\u00f6z A, Vatansever B, Ozt\u00fcrk KH, Akg\u00fcn E. Possibility of Paclitaxel to induce the stemness-related characteristics of prostate cancer cells. Adv Clin Experimental Med. 2021;30(12):1283\u201391.","journal-title":"Adv Clin Experimental Med"},{"key":"1080_CR11","doi-asserted-by":"publisher","first-page":"100800","DOI":"10.1016\/j.mgene.2020.100800","volume":"26","author":"M Ghorbani","year":"2020","unstructured":"Ghorbani M, Pourjafar F, Saffari M, Asgari Y. Paclitaxel resistance resulted in a stem-like state in triple-negative breast cancer: A systems biology approach. Meta Gene. 2020;26:100800.","journal-title":"Meta Gene"},{"issue":"1","key":"1080_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12967-025-06293-w","volume":"23","author":"N Rastegar-Pouyani","year":"2025","unstructured":"Rastegar-Pouyani N, Farzin MA, Zafari J, Haji Abdolvahab M, Hassani S. Repurposing the anti-parasitic agent pentamidine for cancer therapy; a novel approach with promising anti-tumor properties. J Translational Med. 2025;23(1):258.","journal-title":"J Translational Med"},{"key":"1080_CR13","doi-asserted-by":"publisher","first-page":"102624","DOI":"10.1016\/j.tice.2024.102624","volume":"91","author":"N Rastegar-Pouyani","year":"2024","unstructured":"Rastegar-Pouyani N, Abdolvahab MH, Farzin MA, Zare H, Kesharwani P, Sahebkar A. Targeting cancer-associated fibroblasts with pirfenidone: A novel approach for cancer therapy. Tissue Cell. 2024;91:102624.","journal-title":"Tissue Cell"},{"key":"1080_CR14","doi-asserted-by":"publisher","first-page":"121048","DOI":"10.1016\/j.lfs.2022.121048","volume":"309","author":"SA Antar","year":"2022","unstructured":"Antar SA, Saleh MA, Al-Karmalawy AA. Investigating the possible mechanisms of Pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and\/or anti-SARS-CoV-2. Life Sci. 2022;309:121048.","journal-title":"Life Sci"},{"key":"1080_CR15","doi-asserted-by":"publisher","first-page":"173919","DOI":"10.1016\/j.ejphar.2021.173919","volume":"897","author":"V Banerjee","year":"2021","unstructured":"Banerjee V, Sharda N, Huse J, Singh D, Sokolov D, Czinn SJ, et al. Synergistic potential of dual Andrographolide and melatonin targeting of metastatic colon cancer cells: using the Chou-Talalay combination index method. Eur J Pharmacol. 2021;897:173919.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1080_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"T-C Chou","year":"2006","unstructured":"Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621\u201381.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1080_CR17","first-page":"97","volume":"6","author":"N Zhang","year":"2016","unstructured":"Zhang N, Fu JN, Chou TC. Synergistic combination of microtubule targeting anticancer Fludelone with cytoprotective Panaxytriol derived from Panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. Am J Cancer Res. 2016;6(1):97\u2013104.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"1080_CR18","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.3390\/cancers13092188","volume":"13","author":"B Kvoka\u010dkov\u00e1","year":"2021","unstructured":"Kvoka\u010dkov\u00e1 B, Rem\u0161\u00edk J, Jolly MK, Sou\u010dek K. Phenotypic heterogeneity of triple-negative breast cancer mediated by epithelial\u2013mesenchymal plasticity. Cancers. 2021;13(9):2188.","journal-title":"Cancers"},{"key":"1080_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/bs.pmbts.2023.01.010","volume":"197","author":"A Roy","year":"2023","unstructured":"Roy A, Mishra J, Chakraborty S, Singh SP, Patra SK. Epigenetic regulation of pluripotency inducer genes NANOG and SOX2 in human prostate cancer. Prog Mol Biol Transl Sci. 2023;197:241\u201360.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"1","key":"1080_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","volume":"27","author":"FM Howard","year":"2021","unstructured":"Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J. 2021;27(1):8\u201316.","journal-title":"Cancer J"},{"issue":"2","key":"1080_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bbrc.2015.04.107","volume":"462","author":"S-H Choi","year":"2015","unstructured":"Choi S-H, Nam J-K, Jang J, Lee H-J, Lee Y-J. Pirfenidone enhances the efficacy of combined radiation and Sunitinib therapy. Biochem Biophys Res Commun. 2015;462(2):138\u201343.","journal-title":"Biochem Biophys Res Commun"},{"key":"1080_CR22","doi-asserted-by":"publisher","first-page":"102399","DOI":"10.1016\/j.nano.2021.102399","volume":"34","author":"H Deng","year":"2021","unstructured":"Deng H, Yang Y, Zuo T, Fang T, Xu Y, Yang J, et al. Multifunctional ZnO@ CuS nanoparticles cluster synergize chemotherapy and photothermal therapy for tumor metastasis. Nanomed Nanotechnol Biol Med. 2021;34:102399.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"1","key":"1080_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12885-016-2162-z","volume":"16","author":"M Mediavilla-Varela","year":"2016","unstructured":"Mediavilla-Varela M, Boateng K, Noyes D, Antonia SJ. The anti-fibrotic agent Pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer. 2016;16(1):176.","journal-title":"BMC Cancer"},{"issue":"5","key":"1080_CR24","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1039\/D0BM01878C","volume":"9","author":"T Zuo","year":"2021","unstructured":"Zuo T, Zhang J, Yang J, Xu R, Hu Z, Wang Z, et al. On-demand responsive nanoplatform mediated targeting of CAFs and down-regulating mtROS-PYK2 signaling for antitumor metastasis. Biomaterials Sci. 2021;9(5):1872\u201385.","journal-title":"Biomaterials Sci"},{"issue":"1","key":"1080_CR25","doi-asserted-by":"publisher","first-page":"2305279","DOI":"10.1002\/advs.202305279","volume":"11","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Yu R, Zhao C, Liang J, Zhang Y, Su H, et al. CAFs homologous biomimetic liposome bearing BET inhibitor and Pirfenidone synergistically promoting antitumor efficacy in pancreatic ductal adenocarcinoma. Adv Sci. 2024;11(1):2305279.","journal-title":"Adv Sci"},{"issue":"5","key":"1080_CR26","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1007\/s00210-024-03652-0","volume":"398","author":"S-Y Shi","year":"2025","unstructured":"Shi S-Y, Zhao L-W, Liu C-B, Xiao H-M, Jiang Z-J. Pirfenidone promotes cell cycle arrest and apoptosis of triple\u2013negative breast cancer cells by suppressing Hedgehog\/GLI1 signaling. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(5):5915\u201325.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1080_CR27","doi-asserted-by":"publisher","first-page":"113774","DOI":"10.1016\/j.biopha.2022.113774","volume":"155","author":"M Hashemi","year":"2022","unstructured":"Hashemi M, Arani HZ, Orouei S, Fallah S, Ghorbani A, Khaledabadi M, et al. EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions. Biomed Pharmacother. 2022;155:113774.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1080_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10585-008-9170-6","volume":"25","author":"T Blick","year":"2008","unstructured":"Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, Thompson EW. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis. 2008;25(6):629\u201342.","journal-title":"Clin Exp Metastasis"},{"key":"1080_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2017.01.006","volume":"106","author":"A Fujiwara","year":"2017","unstructured":"Fujiwara A, Shintani Y, Funaki S, Kawamura T, Kimura T, Minami M, Okumura M. Pirfenidone plays a biphasic role in Inhibition of epithelial-mesenchymal transition in non-small cell lung cancer. Lung Cancer. 2017;106:8\u201316.","journal-title":"Lung Cancer"},{"issue":"1","key":"1080_CR30","doi-asserted-by":"publisher","first-page":"14357","DOI":"10.1038\/s41598-023-41550-2","volume":"13","author":"H Jamialahmadi","year":"2023","unstructured":"Jamialahmadi H, Nazari SE, TanzadehPanah H, Saburi E, Asgharzadeh F, Khojasteh-Leylakoohi F, et al. Targeting transforming growth factor beta (TGF-\u03b2) using Pirfenidone, a potential repurposing therapeutic strategy in colorectal cancer. Sci Rep. 2023;13(1):14357.","journal-title":"Sci Rep"},{"issue":"3","key":"1080_CR31","doi-asserted-by":"publisher","first-page":"e18059","DOI":"10.1111\/jcmm.18059","volume":"28","author":"S Zhang","year":"2024","unstructured":"Zhang S, Wang Y, Luo D, Cheng Z, Zeng Q, Wang G, et al. Pirfenidone inhibits TGF-\u03b21\u2010induced metabolic reprogramming during epithelial\u2010mesenchymal transition in non\u2010small cell lung cancer. J Cell Mol Med. 2024;28(3):e18059.","journal-title":"J Cell Mol Med"},{"issue":"20","key":"1080_CR32","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.3390\/cancers13205118","volume":"13","author":"HA Es","year":"2021","unstructured":"Es HA, Cox TR, Sarafraz-Yazdi E, Thiery JP, Warkiani ME. Pirfenidone reduces epithelial\u2013mesenchymal transition and spheroid formation in breast carcinoma through targeting cancer-associated fibroblasts (Cafs). Cancers. 2021;13(20):5118.","journal-title":"Cancers"},{"issue":"1","key":"1080_CR33","doi-asserted-by":"publisher","first-page":"9170","DOI":"10.1038\/s41598-017-08971-2","volume":"7","author":"P Mukherjee","year":"2017","unstructured":"Mukherjee P, Gupta A, Chattopadhyay D, Chatterji U. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells. Sci Rep. 2017;7(1):9170.","journal-title":"Sci Rep"},{"issue":"12","key":"1080_CR34","doi-asserted-by":"publisher","first-page":"9823","DOI":"10.1007\/s13277-015-3561-5","volume":"36","author":"Y Li","year":"2015","unstructured":"Li Y, Chen K, Li L, Li R, Zhang J, Ren W. Overexpression of SOX2 is involved in Paclitaxel resistance of ovarian cancer via the PI3K\/Akt pathway. Tumor Biology. 2015;36(12):9823\u20138.","journal-title":"Tumor Biology"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-01080-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01080-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01080-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T14:32:13Z","timestamp":1767882733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-025-01080-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1080"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-01080-1","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require ethical approval as it used established cell lines, in accordance with institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}